Novavax (NVAX) to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory Glenn, M.D., President of Research and Development, will present progress of NVX-CoV2373, Novavax’ coronavirus vaccine candidate, on Wednesday, May 13, 2020 as part of the World Vaccine Congress’ COVID-19 webinar series. Dr. Glenn joins a distinguished group of global public health, epidemiology, regulatory and industry leaders in sharing expertise and information related to the SARS-Cov-2 virus, as well as ongoing efforts to develop vaccines to address the global health pandemic.

Dr. Glenn’s presentation will be followed by a live Q&A discussion. Webinar details are as follows:

Topic: Recombinant Nanoparticle COVID-19 Vaccine: Platform Technology for Emerging Infectious Diseases (EID)Date and Time: Wednesday, May 13, 11:00 a.m. ETModerator: Philip Krause, M.D., Deputy Director, OVRR, CBER, FDA

The webinar is free to attend. To register, please click here.

You May Also Be Interested In

• RegenxBio completes dosing in RGX-202 confirmatory Duchenne study
• INmune Bio gets MHRA alignment for 2026 UK drug application
• Viking Therapeutics starts Phase 1 trial of weight loss drug VK3019